BIBP 3226, the first selective neuropeptide Y1 receptor antagonist: A review of its pharmacological properties

Regulatory Peptides

Volumn 65, Issue 1, 1996, Pages 71-77

  Doods, Henri N ^a   Wieland, Heike A ^a   Engel, Wolfhard ^a   Eberlein, Wolfgang ^a   Willim, Klaus Dieter ^a   Entzeroth, Michael ^a   Wienen, Wolfgang ^a   Rudolf, Klaus ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

BIBP 3226; Neuropeptide Y; NPY antagonist; Y1 receptor subtype

Indexed keywords

NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR SYSTEM; COLON; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

ANIMALIA;

EID: 0030603868     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-0115(96)00074-2     Document Type: Review

References (48)

1. [1] Tatemoto, K., Neuropeptide Y: Complete amino acid sequence of the brain peptide, Proc. Natl. Acad. Sci. USA, 79 (1982) 5485-5489.
2. [2] Zukowska-Grojec, Z. and Wahlestedt C., Origin and actions of neuropeptide Y in the cardiovascular system. In: W.F. Colmers and C. Wahlestedt (Eds.), The Biology of Neuropeptide Y and Related Peptides, Humana Press, Totowa, NJ, 1993, pp. 315-388.
3. [3] Dryden, S., Frankish, H., Qiong Wang and Williams, G., Neuropeptide Y and energy balance: one way ahead for the treatment of obesity?. Eur. J. Clin. Invest., 24 (1994) 293-308.
4. [4] Stanley, B.G., Anderson, K.C., Grayson, M.H. and Leibowitz, S.H., Repeated hypothalamic stimulation with neuropeptide Y increases daily carbohydrate and fat intake and body weight gain in female rats, Physiol. Behav., 46 (1989) 173-177.
5. [5] Maclean, M.R. and Hiley, C.R., Effect of neuropeptide Y on cardiac output, its distribution, regional blood flow and organ resistances in the pithed rat, Br. J. Pharmacol., 99 (1990) 340-342.
6. [6] Edvinsson, L., Emson, P., Häkanson, R. and Wahlestedt, C., Neuropeptide Y potentiates the effects of various vasoconstrictor agents on rabbit blood vessels. Br. J. Pharmacol., 83 (1984) 519-525.
7. [7] Grundemar, L., Mörner, S.E.J.M., Högestätt, E.D., Wahlestedt, C. and Häkanson, R., Characterization of vascular receptors for neuropeptide Y, Br. J. Pharmacol., 105 (1992) 45-50.
8. [8] Pernow. J., Saria, A. and Lundberg, J.M., Mechanisms underlying pre-and postjunctional effects of neuropeptide Y in sympathetic vascular control, Acta Physiol. Scand., 126 (1986) 239-249.
9. [9] Coppes, R.P., Smit, J., Geurtsen, A.M.S., Roffel, A.F., Dahlöf, C., Doods, H.N. and Zaagsma, J., Heterogeneity of prejunctional neuropeptide Y receptors inhibiting noradrenaline overflow in the portal vein of freely moving rats. Eur. J. Pharmacol., 261 (1994) 311-316.
10. [10] Wahlestedt, C.. Yanaihara, N. and Hakanson, R., Evidence for different pre-and post-junctional receptors for neuropeptide Y and related peptides, Regul. Pept., 13 (1986) 307-318.
11. [11] Michel, M.-C., Receptors for neuropeptide Y: Multiple subtypes and multiple second messengers. Trends Pharmacol. Sci., 611 (1991) 392-394.
12. [12] Gehlert, D., Subtypes of receptors for neuropeptide Y: Implications for the targeting of therapeutics, Life Sci., 55 (1994) 551-562.
13. [13] Wan, C.P. and Lau, B.H.S., Neuropeptide Y receptor subtypes, Life Sci., 56 (1995) 1055-1064.
14. 34]neuropeptide Y: A specific Y1 receptor agonist, Proc. Natl. Acad. Sci. USA, 87 (1990) 182-186.
15. [15] Wieland, H.A., Willim, K.D. and Doods, H.N., Receptor binding profile of NPY analoques and fragments in different tissues and cell lines, Peptides, 16 (1995) 1389-1394.
16. [16] Wahlestedt, C.. Regunathan, S. and Reis, D.J., Identification of cultured cells selectively expressing Y1, Y2 or Y3 type receptors for neuropeptide Y/peptide YY, Life Sci., 50 (1991) 7-12.
17. [17] Bard, J.A., Walker, M.W., Branchek, T.A. and Weinshank, R.L., Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y and peptide YY, J. Biol. Chem., 270 (1995) 26762-26765.
18. [18] Castan, I., Valet, P., Voisin, T., Quideau, N., Labuthe, M. and Lafonzan, M., Identification and functional studies of a specific peptide YY-preferring receptor in dog adipocytes, Endocrinology, 131 (1992) 1970-1976.
19. [19] Stanley, B.G., Magdalin, W., Seirafi, A., Nguyen, M.M. and Leibowitz, S.F., Evidence for neuropeptide Y mediation of eating produced by food deprivation and for a variant of the Y1 receptor mediating this peptide's effect, Peptides, 13 (1992) 581-587.
20. [20] Eva, C., Keinanen, K., Monyer, H., Seeburg, P. and Sprengel, R., Molecular cloning of a novel G protein-coupled receptor that may belong to the neuropeptide receptor family, FEBS Lett., 271 (1990) 81-84.
21. [21] Krause, J., Eva, C., Seeburg, P.H. and Sprengel, R., Neuropeptide Y1 subtype pharmacology of recombinantly expressed neuropeptide receptor, Mol. Pharmacol., 41 (1992) 817-821.
22. [22] Rose, P.M., Fernandes, P., Lynch, J.S., Frazier, S.T., Fisher, S.M., Kodukulas, K., Kienzle, B. and Seethala, R., Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide receptor. J. Biol. Chem., 270 (1995) 22661-22664.
23. [23] Rudolf, K., Eberlein, W., Engel, W., Wieland, H.A., Willim, K.D., Entzeroth, M., Wienen, W., Beck-Sickinger, A.G. and Doods H.N., The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP 3226, Eur. J. Pharmacol., 271 (1994) R11-R13.
24. [24] Serradeil-Le Gal C., Valette, G., Rouby, P.E., Pellet, A., Oury-Donat. F., Brossard, G., Lespy, L., Marty, E., Neliat, L., De Cointet, P., Maffrand, J-P. and Le Fur, G., SR 120819A. an orally-active and selective neuropeptide Y Y1 receptor antagonist. FEBS Lett., 362 (1995) 192-196.
25. [25] Snider. R.M., Constantine, J.W., Llowe, J.A., Longo, K.P., Lebel, W.S., Woody, H.A., Drozda, S.E.. Desai, M.C., Vinick, F.J., Spencer, R.W. and Hess, H., A potent nonpeptide antagonist of the substance P (NK1) receptor, Science. 251 (1990) 435-437.
26. [26] Clozel, M., Breu, V., Burri, K., Cassal, J-M., Fischli, W., Gray, GA., Hirth, G., Loeffler, B-M., Mueller, M., Neidhart, W. and Ramuz, H., Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature, 365, 6448, 759-761.
27. [27] Beck-Sickinger. A.G. and Jung, G., Structure-activity relationships of neuropeptide Y analogues with respect to Y1 and Y2 receptors, Biopolymers, 37 (1995) 123-142.
28. [28] Horwell, D.C., Hughes, J., Hunter. J., Pritchard, M., Richardson, R., Roberts, E. and Woodruff, G., Rationally designed 'dipeptoid' analogues of CCK. Alpha-methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties, J. Med. Chem., 34 (1991) 404-414.
29. [29] Beck-Sickinger, A.G., Wieland, H.A., Wittneben, H., Willim, K., Rudolf, K. and Jung, G., Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations, Eur. J. Biochem., 225 (1994) 947-958.
30. [30] Hoffmann, S., Rist, B., Videnov, G., Willim, K.D., Jung, G. and Beck-Sickinger, A.G., Structure-affinity studies of C-terminally modified analogs of neuropeptide Y led to a novel class of peptidic Y1 receptor antagonists, Regul. Pept., 65 (1996) 61-70.
31. [31] Sautel, M.. Rudolf, K., Wittneben, H., Herzog, H., Martinez, R.. Munoz, M., Eberlein, W., Engel, W., Walker, P. and Beck-Sickinger, A., Neuropeptide Y and the non-peptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor, Mol. Pharmacol., submitted.
32. [32] Wieland. H.A., Willim, K.D.. Entzeroth, M., Wienen, W., Rudolf. K., Eberlein, W., Engel, W. and Doods, H.N., Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226, J. Pharmacol. Exp. Ther., 275 (1995) 143-149.
33. [33] Feth. F., Rascher, O. and Michel, M.C., G protein coupling and signalling of Y1-like neuropeptide Y receptors in SK-N-MC cells, Naunyn-Schmiedebergs Arch. Pharmacol., 344 (1991) 1-7.
34. [34] Entzeroth, M., Wieland, H.A., Wienen, W. and Doods, H.N., The increase in renal perfusion pressure by neuropeptide Y is mediated via receptors of the Y1 subtype, Can. J. Physiol. Pharmacol., 72 (1994) Suppl. 1, 170.
35. [35] Doods, H.N. and Krause, J., Different neuropeptide Y receptor subtypes in rat and rabbit vas deferens, Eur. J. Pharmacol., 294 (1991) 101-103.
36. [36] Dumont, Y., Cadieux, A., Pheng, L-H., Fournier, A., St-Pierre, S. and Quirion, R., Peptide YY derivates as selective neuropeptide Y/peptide YY Y1 and Y2 agonists devoid of activity for the Y3 receptor subtype, Mol. Brain Res., 26 (1994) 320-324.
37. [37] Jörgensen, J.Ch., Fuhlendorff, J. and Schwartz, T.W., Structure-function studies on neuropeptide Y and pancreatic polypeptide-evidence for two PP-fold receptors in vas deferens, Eur. J. Pharmacol., 186 (1990) 105-114.
38. [38] Doods, H.N., Wienen, W., Entzeroth, M., Rudolf, K., Eberlein, W., Engel, W. and Wieland, H.A., Pharmacological characterization of the selective nonpeptide NPY Y1 agonist BIBP 3226, J. Pharmacol. Exp. Ther., 275 (1995) 136-142.
39. [39] Jacques, D., Cadieux, A., Dumont, Y. and Quirion, R., Apparent affinity and potency of BIBP 3226, a non-peptide neuropeptide Y antagonist, on purported neuropeptide Y Y1, Y2 and Y3 receptors, Eur. J. Pharmacol., 278 (1995) R3-R5.
40. [40] McAuley, M.R. and Westfall, T.C., Possible location and function of neuropeptide Y receptor subtypes in the rat mesenteric arterial bed, J. Pharmacol. Exp. Ther., 261 (1992) 863-868.
41. [41] Abounader, R., Villemure, J.G. and Hamel, E., Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonists BIBP 3226, Br. J. Pharmacol., 116 (1995) 2245-2250.
42. [42] Zukowska-Grojec, Z., Shen, G.H., Deka-Starosta, A., Myers, A.K. and Kvetnansky, R.M.R., Neuronal, adrenomedullary and platelet-derived neuropeptide Y responses to stress in rats. In: R. Kvetnansky, R. Mccarty and J. Axelrod (Eds.), Stress: Neuroendocrine and Molecular Approaches', Gordan and Breach Science Publishers S.A., New York, 1992, pp. 197-209.
43. [43] Zukowska-Grojec, Z., Shen, G.H., Capraro P.H. and Vaz, C.A., Cardiovascular, neuropeptide Y, and adrenergic responses in stress are sexually differentiated, Physiol. Behav., 49 (1991) 771-777.
44. [44] Zukowska-Grojec, Z., Dayao, E., Karwatowska-Prokopczuk, E., Hauser, G.J. and Doods, H.N., Stress induced mesenteric vasoconstriction in rats is mediated by neuropeptide Y Y1 receptors, Am. J. Physiol., 270 (1995) H796-H800.
45. [45] Modin, A. and Lundberg, J.M., Inhibition of reserpine resistant vasoconstriction in the pig in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226, Br. J. Pharmacol., 116 (1995) 2971-2982.
46. [46] Coppes, R.P., Smit, J., Geurtsen, A.M.S., Roffel, A.F., Dahlöf, C., Doods, H.N. and Zaagsma, J., Heterogeneity of prejunctional neuropeptide Y receptors inhibiting noradrenaline overflow in the portal vein of freely moving rats, Eur. J. Pharmacol., 261 (1994) 311-316.
47. [47] Smit, J., Roffel, A.F., Doods, H.N. and Zaagsma, J., Influence of BIBP 3226, A selective NPY Y1 antagonist, on the NPY-induced inhibition of noradrenaline overflow in swimming spontaneously hypertensive rats, Naunyn-Schmiedeberg's Arch. Pharmacol., 352 (1995) R55.
48. [48] Brown, M.R., communication at the 1995 APS Conference: New Discoveries Within The Pancreatic Polypeptide Family: From Molecules To Medicine. November 8-11, 1995, Newport Beach, CA, USA.